Abstract
Abstract
Pretherapeutic dosimetry is an essential component of individualized
radioiodine therapy. This study aimed to compare radioiodine therapies
planned according to the Marinelli equation or DIN 6861-1:2021-11 with
regard to the deviation of the planned and achieved thyroid doses in
patients with benign thyroid diseases.
The relative deviation of the achieved thyroid dose during radioiodine
therapy from the pretherapeutically planned dose was analyzed according to
the applied dosimetric method. Patient cohorts with goiter, recurrent
goiter, disseminated and focal thyroid autonomy and autoimmune thyroid
disease were evaluated. The cohorts were compared using the Mann–Whitney
U- test.
For goiter, recurrent goiter, disseminated thyroid autonomy and focal thyroid
autonomy, radioiodine therapies planned according to DIN 6861-1:2021-11 were
associated with significantly smaller deviations between the planned and
achieved thyroid doses than therapies planned according to the Marinelli
equation. Depending on the diagnostic group, the mean relative deviation was
approximately 15 to 32 percentage points lower in the DIN cohorts. The DIN
cohorts also showed less variability in dose deviations. In patients with
autoimmune thyroid disease, no statistically significant differences of the
mean relative deviation were observed between the dosimetric methods.
However, variability was also lower in the DIN cohorts.
The use of DIN 6861-1:2021-11 is associated with improved prediction of the
thyroid dose compared with the Marinelli equation and may contribute to more
precise individualized planning of radioiodine therapy in patients with
benign thyroid diseases.